Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
New preclinical data demonstrate that SIL204 treatment produced statistically significant upregulation of FAS (CD95), the immune “death receptor,” and statistically significant downregulation of...
-
Healis Therapeutics opens IND, enabling first U.S. trials for Depression, PTSD, and neuropsychiatric disorders
-
Vantage Biosciences completes enrollment in the Phase 2 SeeClear study of oral oruvestat in non-proliferative diabetic retinopathy.
-
Orelabrutinib in combination with mesutoclax has been granted BTD for the treatment of patients with MZL who have received at least one prior therapy.
-
BCC Research analyzes innovations, trends, competition and regional opportunities shaping single-use technologies in biopharma manufacturing.
-
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
-
NEW YORK, 30 juill. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome...
-
MIRA advances MIRA-55 and SKNY-1 through exploratory toxicology, CMC and manufacturing activities supporting future IND-enabling studies.
-
Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from...
-
Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE)...